Finley John David sold $303K of PALI
Finley John David (CEO, CFO) sold 146,798 shares of PALISADE BIO, INC. (PALI) at $2.07 ($0.30M total) on 2026-07-07.
How this was made
The 30-second read
Why it matters
The disclosure updates the record of insider ownership after an open-market sale, which may influence sentiment but does not provide new operational or financial guidance.
Market read
Traders may monitor for follow-on insider activity or any concurrent company news, but this filing alone is unlikely to drive a durable repricing.
What to watch
The text does not state tax, diversification, or other motives; absence of a 10b5-1 plan could be noise without additional context.
Background
The article is an SEC Form 4 insider transaction for PALISADE BIO, Inc. (PALI) by its CEO/CFO.
Ticker impact
PALISADE BIO CEO/CFO Finley John David sold 146,798 shares in an open-market transaction valued at about $303K on 2026-07-07.
Likely minimal price impact; any effect is short-lived unless followed by additional disclosures or company-specific news.
The filing is a Form 4 insider transaction (open-market sale) with no 10b5-1 plan and no accompanying fundamental catalyst in the text.
Market effects
No sector-level read-across provided; this is company-specific insider activity.
None indicated.
None indicated.
Counterpoint
Insider sales can be liquidity-driven and do not necessarily reflect negative expectations, especially when the transaction is small relative to company value.
Key entities
- issuerPALISADE BIO, INC.
Company whose CEO/CFO reported an open-market sale of shares via SEC Form 4.
- insiderFinley John David
CEO and CFO who sold 146,798 shares at $2.0664 per share.
